Q-omics provides the consensus-scored FOXL3 profile across patient tissues and cancer cell-line models. FOXL3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FOXL3 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, FOXL3 RNA expression shows 5,728 significant pathway-activity associations, with the highest sampling consensus in LGG. Together, these results highlight KIRC, COAD, and LGG as cancer lineages where FOXL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXL3 survival associations across molecular data types. FOXL3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXL3 RNA expression–survival associations across cancer types. High FOXL3 expression shows unfavorable associations in KIRC, CESC, ACC, STAD, OV and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FOXL3 RNA expression.
This table summarizes FOXL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FOXL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXL3 shows lower tumor expression in COAD, LUSC, READ and KICH. The COAD box plot shows higher FOXL3 RNA expression in normal versus tumor tissue (log2 FC = −0.580, t-test p < 0.001).
This table shows molecular features associated with FOXL3 in patient tissues and cancer cell lines. In patient samples, FOXL3 shows the broadest associations at the RNA and protein expression levels, with LGG recurring as the lineage with the largest associated feature set.
